Seeking Alpha
We cover over 5K calls/quarter
Profile| Send Message| ()  

Executives

J.J. Pellegrino - CFO

George LeMaitre - Chairman and CEO

Dave Roberts - President

Analysts

Larry Haimovitch - HMTC

Robert Faulkner - Redmile Group

Mayank Dayani - Cowen and Company

Dominique Sémon - Merlin Nexus

LeMaitre Vascular, Inc. (LMAT) Q1 2009 Earnings Call April 28, 2009 5:00 PM ET

Operator

Welcome to the LeMaitre Vascular first quarter 2009 financial results conference call. At this time, I would like to turn the call over to J.J. Pellegrino, Chief Financial Officer of LeMaitre Vascular. Please go ahead, sir.

J.J. Pellegrino

Thank you, Shanika. Good afternoon and thank you for joining us for our Q1 2009 conference call. Joining me on today’s call is our Chairman and CEO, George LeMaitre, and our President, Dave Roberts.

Before we begin, I would like to read our Safe Harbor statement. Today we will discuss some forward-looking statements, the accuracy of which are subject to risks and uncertainties, where were possible we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, forecast and similar expressions.

Pleased note, these words are not the exclusive means for identifying such statements. Please refer to the cautionary statement regarding forward-looking information and the information under the caption Risk Factors in our 2008 10-K including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.

During the call references will be made to certain non-GAAP measures, which management believes provide additional and meaningful assessment of the core operating performance of the company. Reconciliation of non-GAAP measures to the comparable GAAP measures provided in our earnings release and on the company’s website at www.lemaitre.com.

I will now turn the call over to George LeMaitre.

George LeMaitre

Thanks. I will start by reviewing some Q1 highlights, Dave will then provide a business development update and then J.J. will conclude the call with our Q1 financial results. In the three Q1 headlines for this call: Number one, we posted adjusted operating profit of $211,000, our third consecutive profitable quarter; number two, our gross margin rebounded by 300 basis points to 73%; and number three, sales grew 4% excluding Fx, acquisition and AlboGraft.

With respect to the first headline, Q1’s $211,000 adjusted operating profit was our third consecutive operating profit. This $211,000 operating profit contrasts with the $1.5 million adjusted operating loss, which we posted in Q1 2008 and is more or less inline with our operating profits in Q3 and Q4 of 2008.

At the heart of our recent profitability is the 2008 Expense Shave, which reduced Q1 2009 adjusted operating expenses by 20% versus Q1 2008. Our transformation into a profitable company is now three-quarters old. In the next three quarters, we should see additional operating leverage as sales increase and as AlboGraft-direct plays out.

Moving on to our second headline, in Q1 2009, our gross margin rebounded by over 300 basis points from Q4 2008 to reach 73%. This increase was driven by larger direct-to-hospital presence in Europe as well as improved manufacturing efficiencies.

As in our previous acquisitions, our gross margin frequently dips post-transaction and then repairs as we execute the integration. As a result of our improved gross margin, today we will revising our 2009 bottom line guidance upwards by $300,000 this implies $1.6 million of operating profit over the balance of 2009.

As to our third headline, sales increased 4% versus Q1 2008 excluding foreign exchange, acquisitions and Biomateriali. Sales in North America increased 3%, while international direct-to-hospital sales increased 6%. There were several European stands out in Q1 including Italy, where sales grew more than four-fold and France, where sales grew 37%, both in euros.

Our international direct-to-hospital initiative of the last several years continues to serve us well. Company wide direct-to-hospital sales accounted for 93% of total revenues in Q1, our high water mark. On the other hand, sales to international distributors in Q1 decreased 53% year-over-year reflecting the decreasing in AlboGraft purchases by Edwards as well as decreases in Spain and Greece, our two largest distributor markets.

We believe sales to our international distributors will recover as they complete inventory reduction activities they initiated in response to economic conditions. Likewise in Q1, we have observed US hospitals becoming more reluctant to purchase our 5 Packs, 10 Packs and 20 Packs. Referring instead to order devices one-by-one as the surgeries took place. While I hesitate to outguess the economy, we expect that these inventory work downs will not continue indefinitely as the vast majority of our revenue is tied to major arterial reconstructions.

As a roadmap for what to expect from the AlboGraft transition, perhaps I could focus on our recently completed transition to direct sales in Italy. We bought out our Italian distributor in Q3, 2007. This transition took us five quarters to integrate and Italy have now become our third largest subsidiary behind only the US and Germany.

Now comes, our AlboGraft transition. Given the orderly inventory transfer and the customer information and transition services we purchased, we expect that the AlboGraft transition should be faster and smoother. Indeed AlboGraft sales turned on as expected on March 27th and we have now begun to shift this implant to European hospitals and distributors from our Frankfurt distribution facility.

Selling AlboGraft directly to hospitals should allow us to enjoy an increase in sales, gross margin and operating income. Further upside to AlboGraft-direct could be realized upon receipt of US regulatory approval. This is not baked into our 2009 guidance.

Another item, which gives me cause for top-line optimism is the productivity of our R&D and clinical regulatory departments. In Q1 2009, we received six regulatory approvals. The most significant of which was Chinese approval of our EndoFit Thoracic Stent Graft.

It is likely these six approvals will begin to contribute to revenues in the quarters ahead. We are also happy to report that our UNITE Trial has 34 enrollees, an increase of 12 since December 31, 2008. We are now more than one-third enrolled in this 90-patient, 21 center pivotal trial for our UniFit Abdominal Stent Graft.

The updated sales guidance we are providing today implies a solid sales rebound versus Q1 for the remainder of 2009. I would like to conclude my remarks by reiterating the three Q1 headlines. Number one, we posted adjusted operating profit of $211,000, our third consecutive profitable quarter. Number two, our gross margin rebounded by 300 basis points to 73%. And number three, sales grew 4% excluding Fx, acquisitions and AlboGraft.

I will now turn the call over to Dave Roberts, our President.

Dave Roberts

Thanks, George. In Q1, our business development efforts dropped two more product lines, enabled LMAT sales bag; both our bread and butter implants used by our core customer, the vascular surgeons.

On March 27th, we completed the termination of our contract with Edwards for their distribution of AlboGraft. We paid Edwards 2.25 million euros and repurchased 375,000 euros of inventory. In US dollars, this was $3.5 million cash payment; in exchange Edwards relinquished global distribution rights and provided a detailed sales history and customer transition services.

Immediately following the transaction, we began shipping orders direct to European hospitals. In the near-term, we will focus on establishing relationships between LeMaitre sales rep and the 150 plus active hospital customers in some outlined distributors.

As the year progresses however, we expect to shift our focus towards cross selling other LeMaitre products to these customers as well as to marketing AlboGraft both to dormant and new users. It has been long standing goal to add a Polyester Vascular Graft to our sales bag to the substantial cross selling opportunities we believe exists.

We missed to say, we are pleased to able to complete what we call the back half of the Biomateriali acquisition and finally be in a position to begin to access these sales synergies. Closer to home, we submitted a 510(k) application to the FDA for AlboGraft in 2008. We have early indications that this will not require a perspective clinical trial.

The second implant, we dropped in our sales bag in Q1 was PeriPatch, a biological patch manufactured by Neovasc. On January 26th, LeMaitre became the exclusive distributor in the US and Europe for the patches sized for vascular procedures. These distribution rights run through January 2016 and as the part of this transaction, LeMaitre also obtained an acquisition option starting in 2014.

In its first three months, PeriPatch sales had been encouraging, and reinforce our belief in the synergies between this patch primarily using carotid endarterectomy in our gold standard Pruitt-Inahara Carotid Shunt.

With that, I’ll turn it over to J.J. Pellegrino, our Chief Financial Officer.

J.J. Pellegrino

Thanks, Dave. I will now add some detail on our Q1 operating results and we will conclude with an update of our 2009 guidance. Q1 2009 sales were $11.3 million,a 4% decrease versus Q1 2008. By category, sales decreased 1% in endovascular, 6% in vascular and 3% in general surgery.

Sales decreases within the endovascular category were driven by weaker than expected AlboGraft (inaudible) results. Sales decreases in the vascular category were driven by reduced AlboGraft purchases prior to the Edward’s termination.

It is worth noting that these effects did math positive Q1 sales results. Indeed excluding foreign exchange, acquisitions and Biomateriali, Q1 2009 sales growth was 4% over the year earlier quarter.

We posted 3% and 6% growth in our two largest direct markets, North America and Europe. The company reported a gross margin of 72.8% in Q1 2009, up from 71.7% in Q1 2008, and 69.6% in Q4 2008. This 320 basis points sequential increase was driven by increased direct-to-hospital presence in Europe as well as improved manufacturing efficiencies.

We are pleased to see our margins move back towards the low to mid 70s after the 67% we posted in Q3, 2008. Furthermore, we see some perspective gross margin improvement as we begin to sell AlboGraft directly to hospitals.

Moving down the P&L, operating expenses remained in check. In fact, Q1 2009 operating expenses, excluding restructuring and impairment charges were $8 million, 20% less than in the prior year. The continuing benefits of the 2008 Expense Shave program, was the main driver.

To give you some understanding of just how lean we have become, we ended the quarter with 205 employees, a level we first reached at the beginning of 2005. As a result of this lean approach, sales per employee reached $221,000 in the quarter, up from $120,000 in Q1 2005.

The Q1, 2009 operating loss was $1.6 million versus $2.6 million in Q1 2008. Excluding the $1.8 million AlboGraft termination charge, non-GAAP operating income was $211,000 more or less in line with the prior two quarters' results and significantly improved versus Q1 2008 non-GAAP operating loss of $1.5 million.

The company's continued ability to control costs was evidenced throughout the income statement. Sales and marketing expenses decreased 29% to $4.1 million in Q1 2009. Sales and marketing expenses were 37% of revenue in Q1 2009 compared to 49% in the year earlier quarter, as the company continue to gain operating leverage and strategically focus its marketing resources.

The company started and ended Q1 2009 with 52 sales representatives. General and administrative expenses decreased 11% to $2.5 million in Q1 2009, the result of general belt tightening. R&D expenses increased 3% to $1.3 million in Q1 2009.

Increased product development and regulatory spending was more than offset by reduced process engineering and royalty costs. The company's cash and marketable securities decreased by $4 million during the quarter to $17.3 million, a direct result of $4.1 million in one-time payments.

This $4.1 million cash outlay was comprised of a $3.5 million payment to Edwards and a $575,000 deferred acquisition payment to the sellers of Biomateriali. Only EUR 128,000 of cash payments remained to these sellers due in September 2009. The company continues to maintain a $10 million untapped revolving credit facility.

Turning to our guidance. As a result of continuing currency fluctuations and general economic uncertainty, we reduced our 2009 sales guidance to $48 million to $48.5 million. Excluding foreign exchange and acquisitions, this implies year-over-year sales growth of 2% to 3%.

We also updated our 2009 operating income guidance to break-even from $1.5 million previously, which reflects the Q1 $1.8 million AlboGraft distribution termination charge and our improved gross margin. This is a net increase to our operating income guidance of $300,000 and implies an operating profit of $1.6 million over the balance of 2009. As usual, our top and bottom line guidance excludes the future acquisitions and changes in foreign exchange rates.

With that, I will turn it back over to the operator for Q&A.

Question-and-Answer Session

Operator

(Operator Instructions)

You have a question from the line of Larry Haimovitch of HMTC.

Larry Haimovitch - HMTC

Congrats on a nice solid quarter. Going forward on your guidance, I guess probably J.J. or Dave would be the best to answer this. What assumptions are you making on the Euro? Obviously, you got some tough comparisons in the next couple of quarters because the Euro was so much stronger over last year than this year. Are you looking for the Euro to be about flat with the current level?

J.J. Pellegrino

Yes, thanks for the question Larry. Clearly, last year the Euro made a couple of moves, went up during the first couple of quarters and then down later on in the year. We’re assuming basically a flat Euro from here on out and that’s what included and incorporated into our guidance. We are sort of not in the business of prognosticating what the Euro will do going forward. So, we assume that it will flat.

Larry Haimovitch - HMTC

So, if that happens for the rest of the year, relative to your EUR 48 million approximately guidance for the year. How much of a haircut would you have taken because the Euro declined a couple of million bucks, I am assuming, something like that?

J.J. Pellegrino

Yes, I would say, blended overall year-over-year, probably two, maybe a little more than 2 million is probably a fair gage of the impact of the Euro year-over-year.

Larry Haimovitch - HMTC

And was the reduction, albeit relatively small on the guidance on sales, was that mainly because of the Euro or just a caution of the economy that, we don’t know how the economy is performing and we maybe seeing a little bit impact on procedures.

J.J. Pellegrino

Yes, I’d say, it’s a couple of things. Number one is, clearly we are coming out of maybe a softer Q1 and between the AlboGraft transition issues that we described and the export issues that we described being down by about 50% or so in the quarter. There is probably 40% or more of your guidance revision and so coming out of that weakness, I think you expect those things to repair over time, but they do repair over time. It does take a few quarters maybe and given the broader economic difficulties, I think it make sense to windup, where windup in terms of guidance.

Larry Haimovitch - HMTC

Okay. I do have a couple more questions, but let me jump back in queue and let any one else jump in and then we may come back.

Operator

(Operator Instructions). You have a question from the line of Robert Faulkner of Redmile Group.

Robert Faulkner - Redmile Group

I joined few minutes late. So, forgive me, if you cover this, but you talked about filing the file 510(k) for the graft in the US. Do you have anything in guidance for that?

George LeMaitre

No. We've kept it out of guidance just to, in case we don't get it in '09, I don't want to have to come back and say, we didn't get it, so were pulling down guidance. So, that's not baked in the guidance for '09.

Robert Faulkner - Redmile Group

When did you file it?

George LeMaitre

I think we made our first filing, Q2 '08 and we sent back set of questions within the last three months, Rob. The good news out of it is, we don't think there is a clinical trial involve. So, that's real good news.

Robert Faulkner - Redmile Group

Okay. I guess, you don't, do you want to be in the business of saying when you think you'll get it?

George LeMaitre

No. You've been good enough to ask this question for the last three conference calls and I'm still no closer to giving you good answer. I’d say it feels like it's within 12 months, but I always get burned, when I try to predict, when the FDA is going to say, yes.

Robert Faulkner - Redmile Group

Okay. Perhaps you ran over how transition to your own sales force from let’s say Edwards is going in Europe, but I may have missed it.

Dave Roberts

Yes. George, I’ll take that. This is Dave. Actually, I think it’s going real nicely. We had sort of a real nice professional level of corporation from Edwards and remember this transaction just a month and a day old now.

Robert Faulkner - Redmile Group

Yes.

Dave Roberts

So, it’s still very new to us, but we’ve been very busily selling orders over there, selling to European hospitals. I say, the early indications are good with respect to the type of business that we got, but I’ll also caution as that, it is just a month and it’s probably too soon to tell, but I say logistically things are going just fine.

Robert Faulkner - Redmile Group

Okay. So, that means you’ll keep most of the business that they had or?

George LeMaitre

When we were on this call eight weeks ago, we gave guidance that in '09 we’d see positive impact to sales, gross margin and almost entirely dropping down the operating line. In '09 again of 300,000 euros and so I’d that number right now is wrapped up in our '09 guidance and I guess I’ll stop there.

Robert Faulkner - Redmile Group

So that, that you are sticking with that and it’s going as planned so far even, we are just a month in.

George LeMaitre

That’s right, Rob and I throw in one more thing, which is we opened our mouth the last time and said we are going to do 1 million euros extra in sales in 2010.

Robert Faulkner - Redmile Group

Right.

George LeMaitre

Right, so that’s additional guidance where we actually dipped in 2010, to lets you know about our bullishness about that product.

Robert Faulkner - Redmile Group

Yeah. Okay. And if and when it gets to the US, what kind of impact do you think it can have on your business. I guess one way of thinking about it is what your typical customer already uses for grafts that you could take away from somebody else.

Dave Roberts

Right. And we think it’s about a $180 million worldwide Rob, and maybe $90 million of that sits in the US. So you are going after a significant market and one of our issues in the US is always historically been, we’ve got these great sales reps but they are going after $20 million and $40 million and $50 million niches, and so we are quite optimistic about finally sicking them on a much larger revenue base than we’ve able to historically. So, that is the big part of this story, is getting I think from Europe to United States.

Robert Faulkner - Redmile Group

Okay. So, of $90 million of your customers use how much of that, or is it all $90 million.

Dave Roberts

Yeah. I mean, we are in touch with… I got to say, I always think that we are sort of 40% to 50% geographically penetrated worldwide, lets just call it that in the US, and so, we are going after $50 million of that with the customers that we talk to.

Robert Faulkner - Redmile Group

Okay. Good, great. Okay. That’s it. I will come back if I have anything more.

Operator

Your next question comes from the line of Mayank Dayani of Cowen and Company.

Mayank Dayani - Cowen and Company

Just had one question on guidance again, how conservative is your guidance right now do you think? Because I know, you’ve reiterated your guidance just about a month ago, so how should we think about that?

J.J. Pellegrino

Yes, thanks for the question Mayank. This is J.J.

Mayank Dayani - Cowen and Company

Hi Joe.

J.J. Pellegrino

Yes. I think, we feel good about this revised guidance. Clearly, it's not a position we definitely would particularly want to be into be revising from the previous guidance that we have given you. But given the events of Q1, the effects of sort of the general economy on distributors internationally which was really pretty dramatic. I think we felt that they were reducing their inventories fairly dramatically given their environment over there, and given the sort of large one-time events of the AlboGraft-direct transition, which was not in place at that time. So clearly it wasn't something that we were going to bake into guidance at that time.

Those were two pretty large factors in the revision. So I would say, all things considered moving forward, if we understand those and we think they're going to unwind overtime which we do then we're dealing with sort of the broader economic difficulties on the business and I think we feel pretty comfortable that the numbers that we have given you are reasonable.

George LeMaitre

And I'll take another shot at that as well, to supplement J.J's answer. We've been public, this is our tenth quarter or ninth quarter I think. And we've always hit our own guidance with the exception… this is our first downward revision of our sales guidance. So we've been relatively conservative with these numbers historically and this is just the first time event on that.

Operator

Your next question comes from the line of David Gould of Merlin Nexus.

Dominique Sémon - Merlin Nexus

Yes, hello everyone. This is actually Dominique Sémon.

George LeMaitre

Hello, Dominique.

Dominique Sémon - Merlin Nexus

Hi, guys. I know Dave is on the line or if so.

Dave Roberts

Yes.

Dominique Sémon - Merlin Nexus

Anyway, quick question, could you please, I don't know, who maybe J.J., or David, speak kind of generically about did the financial condition of the company in terms of liquidity and access to capital. I’m asking this because, I think we welcome the strategic moves that we’ve seen taking place in Europe, for example, the acquisition of AlboGraft and Biomateriali and so on.

Our long-term positive goal, you need to finance inventory and so on and you need access to capital to do those and also potentially acquisitions. Should we expect, financing or to see the company sometime in '09 raise capital in a way or another or not?

J.J. Pellegrino

No. To answer the first part of your question, I’d characterize the financial condition of the company is extremely strong. We have a $17.3 million cash balance. We have virtually no debt. We have a $10 million untapped revolver. If our guidance implies about $1.6 million op income for the balance of the year and you’d add back non-cash items, you can get to nice cash generation through the balance of the year.

So, you’ve got a company with strong balance sheet generating cash and puts itself in a good position to do these types of strategic things. So, the termination of the distribution agreement is a great case in point. It was very easy for us to make that decision and buy that piece out given that we had a $21.3 million cash balance at 12/31 '08. So, I’d say we’ve got nice flexibility from a financial strength standpoint and that’s a nice position to be in.

Dave Roberts

Dominique, this is Dave. I’d just add in, you asked about, well if their dry powder for deals and I’d certainly say that, in addition to what J.J. said, even if you took a snapshot right now with $17 million plus of cash in the bank, no debt, plus that $10 million untapped revolver. That gives us lets call it $27 million, you have to subtract out maybe about five of cash if you want to leave it as a buffer, you still talking about $20 million or so liquidity with which to execute these strategic transactions.

Dominique Sémon - Merlin Nexus

Correct.

Dave Roberts

What kind of multiple do you pay? Do you pay one time sales and buy $20 million revenue business or two times sales and buy a 10. That of course depends on the attributes of the business, but that probably balance the upper end of the discussion. And so, we saw the fairly wide range of strategic options with respect to acquisitions and other types of transactions and that’s not even counting in the future cash generation ability of the business, which J.J. described.

Dominique Sémon - Merlin Nexus

Okay, good. So, and lastly, are there any remaining transactions like Biomateriali or AlboGraft that you could engineer in the next few quarters, in your existing portfolio?

George LeMaitre

Can I ask you to ask that question again, one more time, I missed the third word, is it contractions?

Dominique Sémon - Merlin Nexus

No, it was not well asked. So, let me try again. In your current existing product portfolio, are there opportunities to kind of reacquire your control of assets, like you did with AlboGraft or with Biomateriali left that you could work on in ‘09 and 2010 or you think the next addition to products would have to come from outside?

Dave Roberts

Dominique, this is Dave. I’d say, there is sort of nothing, from a product control standpoint. There is nothing that stands out as quite as immediately available. We do have an option to acquire that carotid patch, but that's not for another four or five years. And so in terms of any thing that imminent in terms of sort of buying out of a distribution right or something like that per product line, nothing immediately comes to mind.

George LeMaitre

I would say from a product line perspective, that's true, but as you know, we've been sort of veracious acquirers of our distributors over the years. And so if you took the same concept of what we did to Italy three years ago or two years ago and what we did to AlboGraft just now with Edwards, we're basically buying out the front end of the company. We have access to doing that in a variety of distribution markets, we are direct in probably two-thirds of Europe and then we're only direct in Japan elsewhere. So you lucky places like Australia, South Korea, places like that, you can always do that.

Dominique Sémon - Merlin Nexus

Okay.

J.J. Pellegrino

And Dominique, this is J.J., and I guess, I would finally add that that excludes anything coming out of R&D and regulatory, so we got six approvals this quarter to the extent that we get more approvals, you've got opportunity there and to the extent that our investments in R&D produce new products that we may tell you about in the future, then there will be upside there as well.

Dominique Sémon - Merlin Nexus

Okay. Good. Thanks a lot.

Operator

(Operator Instructions). You have a follow-up question from the line of Larry Haimovitch of HMTC.

Larry Haimovitch - HMTC

I'm glad to see there is lots of question, this is good. So, two questions from me. One, in terms of your reduced guidance, are you seeing impact from the economy on the business I would think modest or little, but just curious if you're seeing a little bit or just being cautious on the guidance.

George LeMaitre

Right. I'll take that. This is George. I do feel like in Q1 we did see a little bit of it in terms of, and I think we talked about this a little bit in the call, but the hospitals and the distributors getting a little bit skiddish about having a financial investment of inventory on their shelves. We believe and we hope this is a one-time adjustment that we've been through, but again, I don’t really know anything about this economy more than you guys know from reading The Wall Street Journal than I know. So, we'll see what happens in the future. It's my gentle sense since we work in the carotid arteries, the thoracic and abdominal aorta and the femorals.

It's my general sense that if any of us needed these bypasses or these interventions that we wouldn’t let them slip for too long. I think the procedures are still taking place. All the information I have in front of me right now is that the procedures are still taking place around the world. But, who knows, we did see something in Q1 and you are seeing us get a little bit, pulling in the horns a little bit on guidance. So, let's see what happens next, but we don’t think the procedures are stopping. We think it's a one-time stocking issue.

Larry Haimovitch - HMTC

Yes, thanks George. Dave, a question for you. Is your acquisition pipeline as full as it has been in the past, I know you are very active in that area, and are you seeing changes in valuations. Obviously, public valuations have dropped substantially. Are you beginning to see or have you seen the private market valuations come into range where you are feeling more hopeful about getting some deals done that you’d like to get done?

Dave Roberts

So, the pipeline, I would say it’s not materially different from what I’ve seen before, Larry. I do think that, I see more companies that are early stage, that are in need of capital or even companies that are further developed, but that are loosing money. And also that are in need of capital. I see more of those opportunities these days. Obviously, I completely agree with you that, you know, to the extend any of our targets are publicly traded. They sort of dropped down with the tide.

But in terms of privately held companies, I would say not necessarily, I still think that if you are a privately held vascular device entrepreneur let's say, and your little company is generating cash. You know, you might be hard pressed to be convinced that your company is worth 50% of what it was worth a year ago. And so, these people can be fairly tenacious about value. So, I would say, not all these privately held entrepreneurs have received the email about valuation yet. But I don’t know, we will see how it all plays out.

Larry Haimovitch - HMTC

Okay. Good. Thanks Dave. Appreciate it.

Dave Roberts

Thank you.

Operator

There are no further questions in the queue at this time. I would like to turn the call back over to Mr. George LeMaitre. Please proceed.

George LeMaitre

Thank you very much, and thank everyone for joining us, and we look forward to our next call.

Operator

Thank you for your participation in today's conference. This does conclude the presentation. You may now disconnect. Good day.

Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.

THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

If you have any additional questions about our online transcripts, please contact us at: transcripts@seekingalpha.com. Thank you!

Source: LeMaitre Vascular, Inc. Q1 2009 Earnings Call Transcript
This Transcript
All Transcripts